QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 26, no. 2 (2007): 450-457
doi: 10.1377/hlthaff.26.2.450
© 2007 by Project HOPE
 
New Online
 * McAllen, TX & Beyond: An Expert Roundtable
 * Geography & Reform
 * Medicaid or Insurance Exchange?
 * Siren Song of New GME
 * Public Plan Option: Pro & Con
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Supplemental Exhibits
* Submit a response to this article
* Comments: View responses
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in ISI Web of Science
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via ISI Web of Science (3)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Scheffler, R. M.
* Articles by Levine, P.
* Search for Related Content
PubMed
* Articles by Scheffler, R. M.
* Articles by Levine, P.
Related Collections
* International Issues
* Maternal And Child Health
* Business Of Health
* Mental Health/Substance Abuse
* Pharmaceuticals
* Health Spending
* Consumer Issues

Health Tracking

TRENDS

The Global Market For ADHD Medications

Richard M. Scheffler, Stephen P. Hinshaw, Sepideh Modrek and Peter Levine

Little is known about the global use and cost of medications for attention deficit hyperactivity disorder (ADHD). Global use of ADHD medications rose threefold from 1993 through 2003, whereas global spending (U.S. $2.4 billion in 2003) rose ninefold, adjusting for inflation. Per capita gross domestic product (GDP) robustly predicted use across countries, but the United States, Canada, and Australia showed significantly higher-than-predicted use. Use and spending grew in both developed and developing countries, but spending growth was concentrated in developed countries, which adopted more costly, long-acting formulations. Promoting optimal prescription and monitoring should be a priority.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
PediatricsHome page
R. M. Scheffler, T. T. Brown, B. D. Fulton, S. P. Hinshaw, P. Levine, and S. Stone
Positive Association Between Attention-Deficit/ Hyperactivity Disorder Medication Use and Academic Achievement During Elementary School
Pediatrics, May 1, 2009; 123(5): 1273 - 1279.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
L. M. Furman
Attention-Deficit Hyperactivity Disorder (ADHD): Does New Research Support Old Concepts?
J Child Neurol, July 1, 2008; 23(7): 775 - 784.
[Abstract] [PDF]

Comments:

Read all Comments

Global Perspective On ADHD: Over- And Underuse
George Halasz
Health Affairs, 21 Mar 2007 [Full text]
Response to Global Perspective On ADHD: Over- And Underuse
Peter L. Levine, et al.
Health Affairs, 26 Mar 2007 [Full text]
ADHD Agents: International Comparisons
Constantine G. Berbatis, et al.
Health Affairs, 9 May 2007 [Full text]


Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2007 Project HOPE–The People-to-People Organization
Terms and Policies